63 results on '"Abruzzo, Lynne V."'
Search Results
2. CytoGPS: A large-scale karyotype analysis of CML data
3. Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia
4. Double minute chromosomes in acute myeloid leukemia, myelodysplastic syndromes, and chronic myelomonocytic leukemia are associated with micronuclei, MYC or MLL amplification, and complex karyotype
5. Del(20q) in patients with chronic lymphocytic leukemia: a therapy-related abnormality involving lymphoid or myeloid cells
6. Second Cancers and Richter Transformation Are the Leading Causes of Death in Patients With Trisomy 12 Chronic Lymphocytic Leukemia
7. B acute lymphoblastic leukemia with t(14;19)(q32;p13.1) involving IGH/EPOR: a clinically aggressive subset of disease
8. Chronic lymphocytic leukemia with t(14;18)(q32;q21)
9. Array Comparative Genomic Hybridization Analysis Identifies Recurrent Gain of Chromosome 2p25.3 Involving the ACP1 and MYCN Genes in Chronic Lymphocytic Leukemia
10. LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients
11. Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression
12. A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
13. microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival
14. Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification
15. Differential expression of CKS-1B in typical and blastoid variants of mantle cell lymphoma
16. The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course
17. Customized Oligonucleotide Array-Based Comparative Genomic Hybridization as a Clinical Assay for Genomic Profiling of Chronic Lymphocytic Leukemia
18. del(15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic myelogenous leukemia
19. Fluorescence in situ hybridization is a useful ancillary diagnostic tool for extraskeletal myxoid chondrosarcoma
20. Whole-Genome Scanning by Array Comparative Genomic Hybridization as a Clinical Tool for Risk Assessment in Chronic Lymphocytic Leukemia
21. Chromosomal abnormalities in Philadelphia chromosome–negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase
22. Sequence analysis proves clonal identity in five patients with typical and blastoid mantle cell lymphoma
23. Identification and Validation of Biomarkers of IgV H Mutation Status in Chronic Lymphocytic Leukemia Using Microfluidics Quantitative Real-Time Polymerase Chain Reaction Technology
24. Aberrant EVI1 expression in acute myeloid leukemias associated with the t(3;8)(q26;q24)
25. MALT1 gene rearrangements and NF-κB activation involving p65 and p50 are absent or rare in primary MALT lymphomas of the breast
26. Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis
27. Translocation (3;8)(q26;q24): a recurrent chromosomal abnormality in myelodysplastic syndrome and acute myeloid leukemia
28. Biological Validation of Differentially Expressed Genes in Chronic Lymphocytic Leukemia Identified by Applying Multiple Statistical Methods to Oligonucleotide Microarrays
29. Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma
30. High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia
31. 39. Chronic lymphocytic leukemia with gain of 2p responds favorably to ibrutinib despite frequent co-occurrence with additional adverse cytogenetic markers
32. Three-Year Follow-up from a Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia
33. Increasing Karyotypic Complexity Predicts Outcomes in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
34. Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation
35. 24. Abbott Vysis IntelliFISH Hybridization Buffer evaluation on hematological specimens
36. 17. CytoGPS: A novel bioinformatics approach for high-throughput karyotype analysis
37. Near-Tetraploidy Is Strongly Associated with Development of Richter's Transformation in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib
38. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens
39. Chronic myeloid leukemia in blast phase associated with t(3;8)(q26;q24)
40. Deletion 15q as the sole abnormality in acute myeloid leukemia: report of three cases and review of the literature
41. Isolated Mesenteric CD20-Positive Myeloid Sarcoma
42. Externally Validated Predictive Clinical Model For Untreated Del(17p13.1) Chronic Lymphocytic Leukemia Patients
43. MD Anderson Scoring System (MDACC) Predicts Outcomes After Hematopoietic Stem Cell Transplantation (HSCT) Better Than Other Prognostic Classifications In MDS
44. Mutational Profile and Prognostic Significance of TP53 in Diffuse Large B-cell Lymphoma Patients Treated with Rituximab-CHOP: A Report From an International DLBCL Rituximab-CHOP Consortium Program Study
45. Myeloid Sarcoma of the Orbit and Ocular Adnexae
46. Feasibility Analysis of Nonmyeloabltive Allogeneic Stem Cell Transplantation (NST) in Patients with Chronic Lymphocytic Leukemia (CLL) and 17p- Deletion,
47. Acquisition of Cytogenetic Abnormalities (CA) Is a Very Poor Prognostic Feature in Patients (pts) with Low and Intermediate-1 (int-1) Risk Myelodysplastic Syndromes (MDS),
48. Mature Results of BEAM/High-Dose Rituximab Vs BEAM/Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) and Autologous Stem Cell Transplantation (ASCT) for Relapsed CD20+ Follicular and Diffuse Large B-Cell Lymphoma: Survival Outcomes and Risk of Secondary Malignancies
49. 4.27 Genomic Variability Predicts Time-to-Treatment in Previously Untreated CLL Patients
50. 3.21 Th17 and non-Th17 IL-17-Expressing Cells in CLL: Delineation, Distribution, and Clinical Relevance
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.